{
    "clinical_study": {
        "@rank": "29945", 
        "arm_group": [
            {
                "arm_group_label": "IDeg followed by IGlar", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "IGlar followed by IDeg", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of the trial is to compare the effect of exercise\n      on blood glucose in subjects with type 1 diabetes, who are treated with either insulin\n      degludec (IDeg) or insulin glargine (IGlar)."
        }, 
        "brief_title": "A Trial Comparing the Effect of Exercise on Blood Glucose in Subjects With Type 1 Diabetes, Who Are Treated With Either Insulin Degludec or Insulin Glargine", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 1"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Type 1 diabetes mellitus (as diagnosed clinically) for at least 12 months\n\n          -  Body mass index 18.0-27.0 kg/m^2 (both inclusive)\n\n          -  Subjects performing regular physical cardiorespiratory activity\n\n          -  Glycosylated haemoglobin (HbA1c) below or equal to 9.5 %\n\n        Exclusion Criteria:\n\n          -  Subject who has donated any blood or plasma in the past month or more than 500 mL\n             within 3 months prior to screening\n\n          -  Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent\n             per day)\n\n          -  Not able or willing to refrain from smoking and use of nicotine substitute products\n             during the inpatient period\n\n          -  Supine blood pressure at screening (after resting for at least 5 minutes) outside the\n             range of 90-140 mmHg for systolic or 50-90 mmHg for diastolic"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 8, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01704417", 
            "org_study_id": "NN1250-3999", 
            "secondary_id": [
                "2012-000329-37", 
                "U1111-1127-3402"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "IDeg followed by IGlar", 
                    "IGlar followed by IDeg"
                ], 
                "description": "Subjects will be randomised to a treatment sequence consisting of two treatment periods in which the subjects will receive IDeg and IGlar, respectively. Administered subcutaneously (s.c., under the skin) once daily. Dose individually adjusted.", 
                "intervention_name": "insulin degludec", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "IDeg followed by IGlar", 
                    "IGlar followed by IDeg"
                ], 
                "description": "Subjects will be randomised to a treatment sequence consisting of two treatment periods in which the subjects will receive IDeg and IGlar, respectively. Administered subcutaneously (s.c., under the skin) once daily. Dose individually adjusted.", 
                "intervention_name": "insulin glargine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glargine", 
                "Insulin", 
                "Insulin, Long-Acting"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "August 9, 2013", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Neuss", 
                    "country": "Germany", 
                    "zip": "41460"
                }
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Trial Comparing the Effect of Exercise on Blood Glucose Between Insulin Degludec and Insulin Glargine in Subjects With Type 1 Diabetes", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Carsten Roepstorff", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "BGpre-exe - BGminimum,exe, difference between blood glucose concentration before exercise and the minimum blood glucose concentration observed during exercise", 
            "safety_issue": "No", 
            "time_frame": "From 0 to 30 minutes"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01704417"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "BGmean,exe, mean blood glucose concentration during exercise", 
                "safety_issue": "No", 
                "time_frame": "From 0 to 30 minutes"
            }, 
            {
                "measure": "BGmean,30-180min,post-exe, mean blood glucose concentration", 
                "safety_issue": "No", 
                "time_frame": "Between 30 and 180 minutes, i.e. post-exercise"
            }, 
            {
                "measure": "BGminimum,30-180min,post-exe, minimum blood glucose concentration", 
                "safety_issue": "No", 
                "time_frame": "Between 30 and 180 minutes, i.e. post-exercise"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}